Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02852798

Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC

Nonsquamous Nonsmall Cell Neoplasm of Lung Clinical Trial

Official title:
Clinical Study of Apatinib Mesylate Tablets Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR Wild-type, Non-squamous, Non-small-cell Lung Cancer

Clinical Trial Summary

This is a clinical study of Apatinib Mesylate Tablets combined with docetaxel monotherapy as second-line therapy of advanced EGFR wild-type, non-squamous, non-small-cell lung cancer.

Clinical Trial Description

In order to seek high-efficiency, low-toxicity anti-angiogenic drugs, Jiangsu Hengrui Medical Co., Ltd has developed an efficient VEGFR2 tyrosine kinase inhibitor (TKI) - Apatinib. This drug works mainly by inhibiting VEGFR2 to produce the anti-angiogenic effects and treat malignant tumors. Apatinib was shown to have good tumor growth-inhibiting activity against lung cancer in both in vivo and in vitro experiments.

This study aims to further validate the efficacy and safety of Apatinib combined with chemotherapeutics in the treatment of advanced EGFR wild-type non-squamous, non-small-cell lung cancer. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02852798
Study type Observational
Source Jiangsu ShengDiYa Medicine Co., Ltd.
Contact JUN JIA
Phone +86 13829139286
Email dgryjy@sina.com
Status Not yet recruiting
Phase N/A
Start date August 2016
Completion date August 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT03380871 - A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer Phase 1
Terminated NCT01373463 - Cisplatin and Pemetrexed With Radiation Followed by Lobectomy Phase 1
Completed NCT02679443 - Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy N/A
Not yet recruiting NCT05764928 - Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy Phase 1/Phase 2
Completed NCT02049060 - Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin Phase 1/Phase 2
Completed NCT02259582 - A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer Phase 2
Completed NCT01814163 - Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab N/A
Terminated NCT02831933 - Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma Phase 2
Terminated NCT02019979 - Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) Phase 2
Completed NCT01705184 - Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. Phase 2
Active, not recruiting NCT03846310 - A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Phase 1